Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial.

Autor: Requena-Ibáñez JA; Atherothrombosis Research Unit, New York, NY, United States; Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, United States. Electronic address: juan.antonio.requena.ib@gmail.com., Santos-Gallego CG; Atherothrombosis Research Unit, New York, NY, United States; Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Rodriguez-Cordero A; Atherothrombosis Research Unit, New York, NY, United States; Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Vargas-Delgado AP; Atherothrombosis Research Unit, New York, NY, United States; Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Badimón JJ; Atherothrombosis Research Unit, New York, NY, United States; Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Jazyk: angličtina
Zdroj: Diabetes & metabolic syndrome [Diabetes Metab Syndr] 2022 Feb; Vol. 16 (2), pp. 102417. Date of Electronic Publication: 2022 Jan 24.
DOI: 10.1016/j.dsx.2022.102417
Abstrakt: Background and Aims: Initially considered as just anti-diabetic agents, SGLT2-i show remarkable cardiac and renal benefits independently of its hypoglycemic activity.
Methods: We used the Kansas City Cardiomyopathy Questionnaire (KCCQ), which has recently been qualified as a Clinical Outcome Assessment, in the EMPATROPISM trial.
Results: A significant mean improvement of 22 points with KCCQ was seen with Empagliflozin versus only 2 points in the Placebo. The proportion of patients experiencing clinically important changes in the Empagliflozin group was higher. Patients with the lowest starting KCCQ score saw significantly greater improvements.
Conclusions: Empagliflozin benefits quality of life in the non-diabetic, ethnic minority represented, EMPATROPISM trial population.
Competing Interests: Declaration of competing interest All authors have read and approved the final version and there is no potential conflict of interest related with this manuscript.
(Copyright © 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: